title: Leukoencephalopathy and papovavirus infection after treatment with chemotherapy and anti-CD20 monoclonal antibody.
authors.forename: Paola
authors.initials: P
authors.lastname: Matteucci
authors.forename: Michele
authors.initials: M
authors.lastname: Magni
authors.forename: Massimo
authors.initials: M
authors.lastname: Di Nicola
authors.forename: Carmelo
authors.initials: C
authors.lastname: Carlo-Stella
authors.forename: Caterina
authors.initials: C
authors.lastname: Uberti
authors.forename: Alessandro M
authors.initials: AM
authors.lastname: Gianni
mesh_terms: D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D017809:Fatal Outcome; D006801:Humans; D007968:Leukoencephalopathy, Progressive Multifocal / Q000209:etiology / Q000821:virology*; D016403:Lymphoma, Large B-Cell, Diffuse / Q000150:complications / Q000188:drug therapy / Q000628:therapy; D008297:Male; D008875:Middle Aged; D030361:Papillomavirus Infections / Q000139:chemically induced*; D000069283:Rituximab
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab